New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
08:37 EDTBMRNBioMarin sees FY14 revenue $650M-$680M, consensus $670.4M
BioMarin Pharmaceutical sees FY14 revenues $650M-$680M, including Naglazyme product revenue $290M-$310M, Kuvan product revenue $180M-$200M and VIMIZIM revenue $60M-$70M. Sees FY14 SG&A expense $265M-$285M, R&D expense $500M-$530M and non-GAAP net loss ($100M)-($130M). Guidance issued in slides for conference call.
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
14:00 EDTBMRNOptions with decreasing implied volatility
Options with decreasing implied volatility: NFLX MLNX XON WUBA MEMP BMRN FTNT BPT SNDK
April 20, 2015
10:11 EDTBMRNOptions with decreasing implied volatility
Options with decreasing implied volatility: BPT WETF NFLX BMRN SNDK STX TSM MAT FAST INTC
07:18 EDTBMRNAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 17, 2015
10:14 EDTBMRNOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use